Vaccinia virus (VACV) confers cross-protective immunity against variola virus, the causative agent of smallpox, and has therefore been extensively exploited as a preventive vaccine. Despite the global ...

Nanoneedle technology offers the capability to simultaneously quantify titers of true, full viral genomes and a range of partial species.

T-cell therapy represents a groundbreaking advancement in the field of immuno-oncology. This innovative treatment involves ...

This article examines viral and non-viral vectors in gene therapy, highlighting their mechanisms, advantages, and limitations ...

A temporally resolved CRISPR-Cas9 screen reveals DAC-induced DNA damage drives trans-cell cycle cytotoxicity that depends on ...

Amid a broader push to beef up cell and gene therapy manufacturing capacity in Europe, Novartis has opened the doors to a €40 ...

Migrant farmworkers are on the front lines of the H5N1 surge — but deportation fears complicate virus surveillance ...

Cell line development plays a pivotal role in the manufacturing of therapeutic proteins, vaccines and other biologics.

Job cuts in Cambridge and Plainville are the second workforce reduction planned for the facilities in the past three months.

Swiss drugmaker Novartis has opened a new viral vector production plant in Menges, central Slovenia, following an investment ...

Viralgen and the CTNNB1 Foundation have come together to manufacture an investigational gene therapy designed to treat CTNNB1 ...

OXB (LSE: OXB), a quality and innovation-led cell and gene therapy CDMO, today announces the appointment of Jefferies International Limited ("Jefferies") as its Joint Corporate Broker and Joint ...